Considerations for BIKTARVY and Methylprednisolone Co-administration

Drug Interaction Profile

BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) has minimal drug-drug interactions with medications metabolized through the CYP450 pathway, including corticosteroids like methylprednisolone, as it is metabolized independently of this pathway 1, 2
InSTI-based regimens such as BIKTARVY are recommended for patients receiving immune-based therapy or treatments for cancer and autoimmune diseases to minimize drug-drug interactions, with an evidence rating of AIIa 1, 2
Bictegravir does not significantly induce or inhibit CYP450 enzymes, making it a preferred option when co-administered with medications like methylprednisolone 2

For patients requiring methylprednisolone for conditions such as autoimmune diseases, transplantation, or cancer treatment, BIKTARVY is a recommended antiretroviral regimen due to its favorable drug interaction profile 1
No dose adjustments are needed for either BIKTARVY or methylprednisolone when co-administered 1, 2

In patients with hepatic impairment receiving methylprednisolone, BIKTARVY should be used with caution in severe hepatic impairment (Child-Pugh C), though no dose adjustment is required for mild to moderate impairment 2, 3

Regular monitoring of HIV viral load is recommended to ensure continued virological suppression when BIKTARVY is co-administered with methylprednisolone 2
Monitor for potential adverse effects of methylprednisolone (e.g. elevated blood sugar, high blood pressure, fluid retention) as usual, as BIKTARVY does not significantly alter the pharmacokinetics of corticosteroids 1
For long-term methylprednisolone therapy, consider bone health monitoring as both HIV infection and corticosteroid use can contribute to bone loss, though BIKTARVY's tenofovir alafenamide component has less impact on bone density than older tenofovir formulations 2

While BIKTARVY has minimal interactions with methylprednisolone, be aware that other medications the patient may be taking could interact with either drug 1
BIKTARVY tablets should not be crushed for patients with difficulty swallowing while on methylprednisolone therapy, as this may affect drug absorption 1